한빛사
>
한빛사논문
한빛사논문
- 조회287
Cancer Res., Dec 01 2023, | https://doi.org/10.1158/0008-5472.CAN-23-1429
Serial circulating-tumor DNA analysis with a tumor naïve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer
Jinho Heo 1,†, Yoo-Na Kim 1,†, Saeam Shin 1, Kyunglim Lee 1, Ji-Hyun Lee 2, Yong Jae Lee 1, Zisun Choi 3, Jihyang Park 3, Seungki Min 4, Sang Wun Kim 1, Jong Rak Choi 5, Sunghoon Kim 1, Seung-Tae Lee 1,*, Jung-Yun Lee 1,*
1Yonsei University College of Medicine, Seoul, Korea (South), Republic of.
2CHA University Ilsan Medical Center, Goyang-si, Gyeonggi-do, Korea (South), Republic of.
3Dxome, Seoul, Korea (South), Republic of.
4dxome, Seoul, Korea (South), Republic of.
5Yonsei University College of Medicine, Korea (South), Republic of.
†Contributed equally to this work
*Corresponding Authors: correspondence to Seung-Tae Lee or Jung-Yun Lee
Abstract
Circulating tumor DNA (ctDNA) may aid in personalizing ovarian cancer therapeutic options. Here, we aimed to assess the clinical utility of serial ctDNA testing using tumor-naïve, small-sized next-generation sequencing (NGS) panels. A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples. Patients received adjuvant therapy based on the current standard of care. Cell-free DNA was extracted and sequenced using an NGS panel of nine genes: TP53, BRCA1, BRCA2, ARID1A, CCNE1, KRAS, MYC, PIK3CA, and PTEN. Pathogenic somatic mutations were identified in 69.2% (139/201) of patients with ovarian cancer at baseline but not in those with benign or borderline disease. Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up; survival did not differ between patients without pathogenic ctDNA mutations in baseline or follow-up samples and those that converted from ctDNA positive to negative. Disease recurrence was also detected earlier with ctDNA than with conventional radiological assessment or CA125 monitoring. These findings demonstrate that serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.
논문정보
- Research article
- 2023년 12월 (BRIC 등록일 2023-12-06)
- 국내 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
